FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2052570036> ?p ?o ?g. }

• W2052570036 endingPage "351" @default.
• W2052570036 startingPage "340" @default.
• W2052570036 abstract "Objective. To evaluate immune responses and clinical outcomes for combined oregovomab and chemotherapy treatment of patients with recurrent ovarian cancer. Methods. Patients with advanced recurrent ovarian cancer were administered oregovomab over 12 weeks before chemotherapy, then optionally concurrent with chemotherapy × 2. Antibody responses, including human anti-mouse antibody (HAMA), anti-idiotypic antibody (Ab2) and anti-CA125, were assessed by ELISA; T-cell responses to CA125, autologous tumor and oregovomab by interferon (IFN)-γ enzyme-linked immunoSPOT (ELISPOT) were also evaluated. Clinical outcomes were recorded. Results. Twenty patients were enrolled; median follow-up was 15.8 months. Oregovomab was well tolerated and did not produce drug-related serious adverse reactions. In 15/19 (79%) patients, robust treatment-emergent humoral responses were observed to the constant (HAMA) and variable region (Ab2) of oregovomab, and 2/19 (11%) patients developed anti-CA125 antibodies. Significant increases in T-cell responses were measured in 7/18 (39%) patients in response to CA125, in 5/8 (63%) patients in response to autologous tumor and in 9/18 (50%) patients in response to oregovomab. Immune responses appeared by week 12 (four doses) and were generally maintained or augmented in patients continuing combined treatment with oregovomab and chemotherapy. Median survival was 70.4 weeks (4.6–141.6 weeks), and the median progression-free interval was 11 weeks (2.6–114.6 weeks). Patients who mounted a T-cell response to CA125 and/or autologous tumor showed significantly improved survival (median not reached vs. 51.9 weeks, P = 0.002) compared to patients who did not. Conclusions. Oregovomab was well tolerated and induced multiple antigen-specific immune responses, maintained during concomitant chemotherapy. A significant survival benefit was observed in patients mounting a T-cell response to CA125 and/or autologous tumor." @default.
• W2052570036 created "2016-06-24" @default.
• W2052570036 creator A5020982105 @default.
• W2052570036 creator A5027346475 @default.
• W2052570036 creator A5041505169 @default.
• W2052570036 creator A5050172772 @default.
• W2052570036 creator A5050867417 @default.
• W2052570036 creator A5057469474 @default.
• W2052570036 creator A5070555068 @default.
• W2052570036 date "2004-08-01" @default.
• W2052570036 modified "2023-10-03" @default.
• W2052570036 title "CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients" @default.
• W2052570036 cites W1550301398 @default.
• W2052570036 cites W1711013043 @default.
• W2052570036 cites W1966864407 @default.
• W2052570036 cites W1972777297 @default.
• W2052570036 cites W1976913414 @default.
• W2052570036 cites W1999710180 @default.
• W2052570036 cites W2007035782 @default.
• W2052570036 cites W2014947083 @default.
• W2052570036 cites W2025488459 @default.
• W2052570036 cites W2053353274 @default.
• W2052570036 cites W2064291021 @default.
• W2052570036 cites W2067560247 @default.
• W2052570036 cites W2088279827 @default.
• W2052570036 cites W2093252833 @default.
• W2052570036 cites W2094483074 @default.
• W2052570036 cites W2124749346 @default.
• W2052570036 cites W2130867278 @default.
• W2052570036 cites W2132731224 @default.
• W2052570036 cites W2137074525 @default.
• W2052570036 cites W2150727952 @default.
• W2052570036 cites W2176970360 @default.
• W2052570036 cites W2219567089 @default.
• W2052570036 cites W3187582577 @default.
• W2052570036 cites W2067317780 @default.
• W2052570036 doi "https://doi.org/10.1016/j.ygyno.2004.04.024" @default.
• W2052570036 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15297171" @default.
• W2052570036 hasPublicationYear "2004" @default.
• W2052570036 type Work @default.
• W2052570036 sameAs 2052570036 @default.
• W2052570036 citedByCount "75" @default.
• W2052570036 countsByYear W20525700362012 @default.
• W2052570036 countsByYear W20525700362013 @default.
• W2052570036 countsByYear W20525700362014 @default.
• W2052570036 countsByYear W20525700362015 @default.
• W2052570036 countsByYear W20525700362016 @default.
• W2052570036 countsByYear W20525700362017 @default.
• W2052570036 countsByYear W20525700362018 @default.
• W2052570036 countsByYear W20525700362019 @default.
• W2052570036 countsByYear W20525700362020 @default.
• W2052570036 countsByYear W20525700362021 @default.
• W2052570036 countsByYear W20525700362022 @default.
• W2052570036 crossrefType "journal-article" @default.
• W2052570036 hasAuthorship W2052570036A5020982105 @default.
• W2052570036 hasAuthorship W2052570036A5027346475 @default.
• W2052570036 hasAuthorship W2052570036A5041505169 @default.
• W2052570036 hasAuthorship W2052570036A5050172772 @default.
• W2052570036 hasAuthorship W2052570036A5050867417 @default.
• W2052570036 hasAuthorship W2052570036A5057469474 @default.
• W2052570036 hasAuthorship W2052570036A5070555068 @default.
• W2052570036 hasConcept C121608353 @default.
• W2052570036 hasConcept C126322002 @default.
• W2052570036 hasConcept C126894567 @default.
• W2052570036 hasConcept C143998085 @default.
• W2052570036 hasConcept C159654299 @default.
• W2052570036 hasConcept C203014093 @default.
• W2052570036 hasConcept C2776090121 @default.
• W2052570036 hasConcept C2776694085 @default.
• W2052570036 hasConcept C2779053233 @default.
• W2052570036 hasConcept C2780427987 @default.
• W2052570036 hasConcept C71924100 @default.
• W2052570036 hasConcept C8891405 @default.
• W2052570036 hasConcept C90924648 @default.
• W2052570036 hasConceptScore W2052570036C121608353 @default.
• W2052570036 hasConceptScore W2052570036C126322002 @default.
• W2052570036 hasConceptScore W2052570036C126894567 @default.
• W2052570036 hasConceptScore W2052570036C143998085 @default.
• W2052570036 hasConceptScore W2052570036C159654299 @default.
• W2052570036 hasConceptScore W2052570036C203014093 @default.
• W2052570036 hasConceptScore W2052570036C2776090121 @default.
• W2052570036 hasConceptScore W2052570036C2776694085 @default.
• W2052570036 hasConceptScore W2052570036C2779053233 @default.
• W2052570036 hasConceptScore W2052570036C2780427987 @default.
• W2052570036 hasConceptScore W2052570036C71924100 @default.
• W2052570036 hasConceptScore W2052570036C8891405 @default.
• W2052570036 hasConceptScore W2052570036C90924648 @default.
• W2052570036 hasIssue "2" @default.
• W2052570036 hasLocation W20525700361 @default.
• W2052570036 hasLocation W20525700362 @default.
• W2052570036 hasOpenAccess W2052570036 @default.
• W2052570036 hasPrimaryLocation W20525700361 @default.
• W2052570036 hasRelatedWork W1905845355 @default.
• W2052570036 hasRelatedWork W1967715255 @default.
• W2052570036 hasRelatedWork W1972821856 @default.
• W2052570036 hasRelatedWork W2242587286 @default.
• W2052570036 hasRelatedWork W2383265090 @default.
• W2052570036 hasRelatedWork W2392413698 @default.

• next